Immix Biopharma subsidiary Nexcella raises ~$650k in private placement at $6.49/share

Immix Biopharma, Inc.

Nexcella entered share purchase agreements with accredited investors for 100,152 shares at $6.49/share.
Gross proceeds of approximately $650,000; after closing, Nexcella has 6,357,444 shares outstanding.
Offering exempt under Section 4(a)(2) and Rule 506 of Regulation D; shares are restricted securities.
Shares subject to drag-along rights and potential 365-day lock-up upon any future IPO of the subsidiary.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immix Biopharma, Inc. entered into Purchase Agreements with certain accredited investors valued at approximately $650,000 (effective 2023-01-12).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $650,000
Effective: 2023-01-12

Exact text from the filing

On January 12, 2023, Nexcella, Inc. (“Nexcella”), a subsidiary of Immix Biopharma, Inc. (collectively, the “Company”) entered into share purchase agreements (the “Purchase Agreements”) with certain accredited investors for their purchase of an aggregate 100,152 shares of Nexcella’s common stock at a purchase price of $6.49 per share, for gross proceeds of approximately $650,000 (the “Private Placement”).

View on SEC.gov

Browse all material agreements →

Immix Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-001795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.